223 related articles for article (PubMed ID: 20166202)
21. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
Wood AC; Maris JM; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Wu J; Kurmasheva RT; Whiteman K; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Nov; 60(11):1860-7. PubMed ID: 23798344
[TBL] [Abstract][Full Text] [Related]
22. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
23. Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.
Riesterer O; Yang Q; Raju U; Torres M; Molkentine D; Patel N; Valdecanas D; Milas L; Ang KK
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1179-87. PubMed ID: 21129859
[TBL] [Abstract][Full Text] [Related]
24. Initial testing of dasatinib by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
[TBL] [Abstract][Full Text] [Related]
25. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.
Carol H; Reynolds CP; Kang MH; Keir ST; Maris JM; Gorlick R; Kolb EA; Billups CA; Geier B; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB
Pediatr Blood Cancer; 2013 Apr; 60(4):633-41. PubMed ID: 22753001
[TBL] [Abstract][Full Text] [Related]
26. Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
Smith MA; Maris JM; Lock R; Kolb EA; Gorlick R; Keir ST; Carol H; Morton CL; Reynolds CP; Kang MH; Houghton PJ
Pediatr Blood Cancer; 2011 Aug; 57(2):268-74. PubMed ID: 21360650
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
[TBL] [Abstract][Full Text] [Related]
28. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
[TBL] [Abstract][Full Text] [Related]
29. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
Keir ST; Maris JM; Lock R; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2010 Dec; 55(6):1126-33. PubMed ID: 20672370
[TBL] [Abstract][Full Text] [Related]
30. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
Wu KD; Zhou L; Burtrum D; Ludwig DL; Moore MA
Cancer Immunol Immunother; 2007 Mar; 56(3):343-57. PubMed ID: 16832681
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
32. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
33. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.
Smith MA; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Kang MH; Reynolds CP; Maris JM; Watkins AE; Houghton PJ
Pediatr Blood Cancer; 2010 Feb; 54(2):307-10. PubMed ID: 19856388
[TBL] [Abstract][Full Text] [Related]
34. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
[TBL] [Abstract][Full Text] [Related]
35. Initial testing of topotecan by the pediatric preclinical testing program.
Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB
Pediatr Blood Cancer; 2010 May; 54(5):707-15. PubMed ID: 20017204
[TBL] [Abstract][Full Text] [Related]
36. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
[TBL] [Abstract][Full Text] [Related]
37. Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma.
Shackleford TJ; Hariharan S; Vaseva AV; Alagoa K; Espinoza M; Bid HK; Li F; Zhong H; Phelps DA; Roberts RD; Cam H; London CA; Guttridge DC; Chen Y; Rao M; Shiio Y; Houghton PJ
Mol Cancer Ther; 2023 Apr; 22(4):539-550. PubMed ID: 36696581
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
39. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock R; Carol H; Reynolds CP; Maris JM; Wu J; Smith MA
Pediatr Blood Cancer; 2009 Oct; 53(4):594-8. PubMed ID: 19554571
[TBL] [Abstract][Full Text] [Related]
40. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Reynolds CP; Kang MH; Carol H; Lock R; Gorlick R; Kolb EA; Kurmasheva RT; Keir ST; Maris JM; Billups CA; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 May; 60(5):791-8. PubMed ID: 23002019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
